Research Participant Registry Join Now!
Immune System/Infections

If you are interested in hearing more about one or more of the studies listed below, and you are already a Registry participant, please contact the Research Participant Registry at 1-866-438-8230 or via e-mail

ACTG A5350 University of Pittsburgh PRO16010187
Researchers would like to study a probiotic called Visbiome Extra Strength to see if it can decrease inflammation in people living with HIV. Eligible participants are HIV-positive men and women who are taking HIV medications (for at least 48 weeks), have an undetectable viral load, and have a CD4 count greater than 200. Participation will last about 44 weeks or 11 months. Compensation provided.

FACE-PC: Family-Centered Care for Older Adults with Depression and Chronic Medical Conditions in Primary Care University of Pittsburgh PRO14040546A
Do you have multiple medical conditions and are you feeling depressed? If so, you may be eligible to participate in a study to help older adults with depression and chronic medical conditions, and their loved ones, to manage their health. Must be age 60 or older, currently depressed or have been treated for depression within the past year, and must have one or more chronic medical conditions.

The Vacation Study University of Pittsburgh PRO15060504
Are you an adult HIV-uninfected, gay/bi male (born male) who is planning to take a vacation in the next few months? Have you had unprotected anal sex in the past year? If so, you may be eligible to participate in a study to help investigators test the feasibility and acceptability of short-term PrEP. PrEP can reduce the risk of HIV-infection in HIV-uninfected gay/bi men. Compensation provided.

A Dose-Finding Study of GSK2894512 Cream in Subjects with Atopic Dermatitis (AD) Schulman Associates Institutional Review Board, Inc. 201600546B
Are you between 18-65 years old and have you been diagnosed with atopic dermatitis (eczema)? If so, you may be eligible to participate in a study to look at how different concentrations of a study cream, GSK2894512, affects atopic dermatitis. Participation lasts about 4-5 months total. Participants will be compensated.

The ENRGISE Study University of Pittsburgh PRO15060563
Are you age 70 or older and having difficulty walking several blocks or climbing a flight of steps? If so, you may be eligible to participate in a study to test if study medications will reduce the level of inflammation in your blood and see if this improves mobility and function. Participation will last about 12 months. Compensation provided.

EpiPrEP Pitt Pilot Study University of Pittsburgh PRO15010326
Are you a HIV-negative man who has sex with other men? Are you planning on going away on vacation soon? If so, you may be eligible to participate in a study to help investigators test the feasibility and acceptability of short-term PrEP. PrEP is taking medications typically used to treat HIV to help prevent HIV. Compensation provided.

ACTG A5324 University of Pittsburgh PRO15010378
Are you HIV-infected and are you having problems with your memory or daily activities? If so, you may be eligible to help researchers see if adding study drugs maraviroc (MVC) and/or dolutegravir (DTG) to your current medication regimen will improve your ability to concentrate, remember, solve problems and make decisions. Study participation will last about 96 weeks. Compensation provided.

ACTG A5342 University of Pittsburgh PRO15040387
Are you between the ages of 18 and 65 and HIV-infected? Have you been on continuous ART for 2 years, and do you have a CD4 count over 200? If so, you may be eligible to help researchers see if an experimental monoclonal antibody called VRC01 is safe and well-tolerated in HIV positive people and to see if VRC01 helps reduce the number of HIV infected cells in the body. Compensation provided.

ACTG A5346: Trial for Sitagliptin for Reducing Inflammation and Immune Activation University of Pittsburgh PRO15070233
HIV-infected adults needed for a study to help researchers evaluate whether a FDA-approved drug (sitagliptin) that is used to treat type 2 diabetes can reduce inflammation and immune activation markers in HIV-infected men and women who are taking antiretroviral medication when compared to placebo (dummy pill). Study participation will last up to 8 months. Travel costs reimbursed.

REPRIEVE Heart Study University of Pittsburgh PRO15010395
Participants are invited to join a study about heart disease prevention in people with HIV. Eligible participants are between 40-75 years old, have been on retroviral therapy (ART) for at least 6 months, have a CD4+ cell count>100, have no history of cardiovascular disease, and are not currently using a statin drug. Study participation will last approximately 72 months. Compensation provided.

ACTG A5320 PRO14010146
Have you been in a Hepatitis C treatment research study within the past year? If so, you may be eligible to participate in a study where your experience can help researchers develop better ways to treat Hepatitis C. Study visits are twice a year, plus a visit before starting any new Hepatitis C treatment. No medications are provided by this study. Parking/travel-related expenses reimbursed.

ACTG A5314 PRO13090071
Are you at least 40 years of age? Are you HIV-1 positive? People who have an undetectable HIV viral load while on HIV medications for the past 6 months, have a CD4 cell count of at least 400, and have active heart disease or are at risk for heart disease may be eligible to participate in this study that will look at the effects of a medication on inflammation and heart health in those with HIV.

ENT Research – Ragweed Study PRO13040368A
Do you have ragweed allergy? Are you a relatively healthy adult between the ages of 18 and 50? If so, you may be eligible to participate in a study to determine if allergic rhinitis (nasal allergy) increases the rate of blood-flow in the lining of the middle ear. This study requires three visits to Children’s Hospital of Pittsburgh. Compensation provided.

CHIC II Study PRO11120183
Are you a generally healthy woman between the ages of 18 and 34 years old who has regular periods? If so, and if you are not pregnant or currently using hormones for birth control, you may be eligible to participate in a study to better understand how birth control affects the immune cells within the reproductive tract. Compensation is provided.

HIV Prevention Research Registry PRO11110371
Are you interested in learning about HIV prevention research studies taking place at the University of Pittsburgh and UPMC? If so, you can join the HIV Prevention Research Registry. HIV prevention registry members may be contacted by registry staff members about studies for which they appear to qualify. Eligible participants are ages 18 and older.

To find out about the Research Participant Registry and opportunities to participate in research studies (or to withdraw from the Registry),
contact or call 1-866-438-8230.
This website is maintained by the Clinical and Translational Science Institute.
If you have any technical difficulty please submit your help request here.
© Office of the Senior Vice Chancellor for the Health Sciences, University of Pittsburgh. All rights reserved.